Montara Therapeutics
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Montara Therapeutics is a San Francisco-based precision medicine neuroscience biotech developing safer, more efficacious therapies for patients with neurological diseases. Many promising brain drug candidates fail due to serious side effects outside the brain. Our BrainOnly™ platform solves this by pairing a brain-targeted treatment with a "blocker" drug that confines therapeutic activity to the brain, enhancing safety, expanding therapeutic index, and unlocking previously inaccessible targets. The science originated in Kevan Shokat's lab at UCSF. Our lead program targets Tuberous Sclerosis Complex with an IND filing targeted for Q1 2027. Our second program targets Parkinson's disease via our BrainTAC™ technology, supported by the Michael J. Fox Foundation. With broad CNS applicability, BrainOnly™ holds the potential to deliver a new generation of brain-targeted therapeutics. Montara has raised $28M from Two Bear Capital, the Dementia Discovery Fund, KdT Ventures, and others.
Company HQ City:
San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2024
Lead Product in Development:
MTX-E1 for treatment of TSC-related seizures
CEO
Nicholas T. Hertz, PhD
President & Chief Executive Officer
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
NA
When you expect your next catalyst update?
January, 2027
What is your next catalyst (value inflection) update?
FIH trials for the first program
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}